Corporate Fact Sheet

*Information correct 02 November 2016

AIM listing

Relocation

WEP acquisition

July 2014

May 2014

August 2014

July 2013

January 2012Addition of novel

polymers

Abzena listed on AIM raising £20m

Abzena plc move to Cambridge, UK

Large and growing marketAbzena operates in a large and growing market with biopharmaceutical companies expected to outsource about $4.1bn of biomanufacturing work by 2019 and sales of antibody drug conjugates (ADCs), a combination of an antibody and a highly potent drug, predicted to be $12.7bn by 2020. ADCs are just part of the growing $163bn biopharmaceutical market.

Global businessAbzena is a global business with customers all over the world. Its headquarters and main R&D laboratories are in Cambridge (UK) and it has manufacturing and laboratory facilities in San Diego (CA, USA) and Bristol, near Philadelphia (PA, USA). The US operations were acquired in the second half of 2015 (see side panel for a history of the business). Abzena was admitted to the Alternative Investment Market (AIM) of the London Stock Exchange in July 2014.

Potential for signi� cant future licensing revenuesAbzena’s services and technologies provide two sources of income:

• Fee for service income from � xed price and full time equivalent based contracts

• Technology licence milestones and/or royalties from the development and commercialisation of ‘Abzena inside’ products - those whose properties have been enhanced by Abzena’s technologies

Abzena has more than 40 technology licence and option agreements covering its ADC linker, antibody humanisation and protein deimmunisation and technologies. The latter two reduce the risk of therapeutic antibodies and other proteins producing an unwanted e� ect in patients. There are 11 therapeutic antibodies produced using Abzena’s humanisation technology being progressed through clinical development by its partners (see reverse).

TICKER: ABZA

Antitope acquisition

£11m new capital raised in conjunction with acquisition

Abzena created

PolyTherics group rebranded as Abzena

4 years of signi� cant progress…..4 rounds of � nancing, including an IPO, and 4 acquisitions

Provider of specialist services and technologiesAbzena provides a suite of proprietary technologies and complementary services to organisations involved in the research and development (R&D) of new biopharmaceutical products, drug therapies based on proteins such as antibodies, to enable the selection and development of better products.

Abzena also manufactures biopharmaceuticals and can synthesize highly potent drugs for use in R&D. The Group can provide a broad range of services from antibody discovery to manufacture of products for clinical

Executive Management Board of Directors

John Burt†

Chief Executive O� cer

Ken Cunningham Chair

Julian Smith†

Chief Financial O� cer

John ManzelloPresident, Abzena US

Sven LeeChief Business O� cer

Sally WatermanSVP Corporate Development

Donna HackettSVP IP, Commercial & Legal A� airs

Leigh PierceChief Technology O� cer

Campbell BunceSVP Scienti� c Operations

Nareshkumar JainSVP ADC Biomanufacturing & Global Head of Chemistry

Jim MillsSVP Technical Operations

Paci� cGMP acquisitionSeptember 2015

Addition of process development and GMP manufacturing

TCRS acquisitionDecember 2015

Addition of chemistry services for ADC manufacture

£20m raised

Placing of 35,004,972 ordinary shares

November 2015

Tony Brampton Partner, Longbow Capital

Nigel Pitchford Chief Investment O� cer, Imperial Innovations

Peter GrantCEO, Skyepharma PLC

†John Burt and Julian Smith also on board

www.abzena.com email: info@abzena.com

3.7

5.4

9.6FY 15/16

FY 14/15

FY 13/14

Service Revenue (£m)

FY 13/14 (re-stated)

Denceptor formed Abzena and Baylor

Institute to develop novel immunotherapies

Technology overview

www.abzena.com UK +44 1223 903498 USA +01 215 788 3603 *Information correct 02 November 2016

Abzena has a mixed business model with growing service revenues and potential upside from technology licence revenue.

Service revenues Licence revenues

Composite CHO™ to produce cell lines for the manufacture of therapeutic antibodies

Composite Protein™ technology to create less immunogenic therapeutic proteins

Composite Human Antibody™ technology to create less immunogenic therapeutic antibodies

iTope and TCED™ technologies to identify parts of proteins and antibodies that could be immunogenic

EpiScreen™ for assessment of the immunogenicity of biopharmaceuticals

ThioBridge™ for linking antibodies that target tumours to cancer drugs

TheraPEG™, CyPEG™ and HiPEG™ for linking polymers to therapeutic proteins to extend their duration of action

GMP manufacture of biopharmaceuticals for Phase I & II clinical studies and non-GMP production using single-use equipment

Process development to optimise upstream and downstream production as a standalone service or integrated with a manufacturing project

Composite Human Antibodies™ in clinical development*Milestone and/or royalty payments due to Abzena if the antibodies progress through development and reach the market.

Company & product candidate Potenti al indicati ons Phase I Phase II Phase III

Gilead Sciences – GS-5745 Gastric cancer, RA, cysti c fi brosis

Opsona Therapeuti cs – OPN-305 DGF & myelodysplasti c syndrome

Vascular Pharmaceuti cals – VPI-2690B Diabeti c nephropathy

True North Therapeuti cs – TNT009 Cold aggluti n disease & anti body-driven diseases

Roche – RG 6125 (SDP051) RA, fi broti c conditi ons, cancer

NKT Therapeuti cs – NKTT120 Sickle cell disease

Therapure Innovati ons – TBI 304H Chemotherapy-induced anaemia

4 Undisclosed companies Undisclosed

RA = rheumatoid arthriti s; DGF = delayed graft functi on

Manufacture of ADCs for evaluation and preclinical studies using ThioBridge™ or other proprietary or non-proprietary conjugation chemistries

Toolbox of cytotoxic payloads and synthesis of payload-linker combinations for ADCs, and custom synthesis of other reagents and small molecules